Novartis MAXIMISEs Cosentyx PsA Position
Executive Summary
Up to two thirds of patients with psoriatic arthritis experience inflammatory back pain and the Swiss major has presented data showing that its best-selling drug achieved rapid and significant improvements.
You may also be interested in...
Novartis Q4 Preview: Launches Likely To Deliver
Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.
Novartis Eyes Fourth Approval For Cosentyx
As Novartis files Cosentyx for non-radiographic axial spondyloarthritis, it is becoming increasingly clear that psoriasis will not be the blockbuster's revenue growth driver going forward.
Tremfya And Taltz Provide PsA Highlights At EULAR
The spotlight was on anti-interleukin drugs at the Madrid meeting last week, especially their role in advancing the treatment of psoriatic arthritis.